Moreover, BDNF-TrkB signaling in striatal D1-MSNs has a protective effect against the development of levodopa-induced dyskinesias (LID), with targeted activation of TrkB agonists reducing LID severity56. This evidence concerns the gene NTRK2 and Dyskinesia.